China Vaccine Industry shall expand at a CAGR of nearly 11.97% from 2023-2027. Catalysed by government support for the healthcare sector, and advancements in vaccine research & development
31 Jul, 2023

Renub Research has lately released a file named "China Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2027," presenting a detailed industry analysis that consists of market share insights. In addition, the document covers studies on competitors and areas and contemporary advancements inside the China Vaccine Market.

China Vaccine Market will reach US$ 12.16 Billion by 2027. With a populace anticipated at 1.42 Billion according to the United Nations Population Fund's (UNFPA's) "State of World Population Report, 2023", China's excessive demand for vaccines to prevent and manipulate infectious sicknesses is further magnified, a trend that has intensified with the outbreak of COVID-19, no longer just within China but globally.

The vaccine industry in China has visible enormous government investment, imparting incentives to inspire local corporations to develop and convey vaccines. As a result, Chinese vaccine producers have made incredible strides within the research and development of latest vaccines, with some even earning international recognition for their efficacy and modern practices.

Category 1 & 2 Vaccines in China

In China, Category 1 vaccines, important for public health and part of the countrywide immunization software, are supplied to citizens at no cost because the authorities subsidize them. Some examples of those vaccines in China are measles, polio, and hepatitis B. In addition, the Chinese authorities has made great investments in the vaccine company, providing incentives and funding to guide the improvement and production of vaccines, boosting the deliver and availability of vaccines, which include Category 1 vaccines sponsored by the authorities.

Category-2 vaccines in China, such as vaccines for pneumococcal disease, influenza, and rabies, aren't authorities-subsidized or a part of the countrywide immunization program. These vaccines are to be had for buy by using individuals or healthcare vendors. The surge of the middle elegance in China has caused more spending on healthcare, together with Category 2 vaccines. At the same time, the growing older population has also contributed to their boom as older adults are looking for preventive measures in opposition to certain illnesses.

Sectors – Vaccine Market & Doses in China

•    Public
•    Private

Meningococcal meningitis and DTP Vaccine are tremendous inside the China Vaccine Market.

Outbreaks of meningococcal meningitis in China have created an excessive demand for vaccines towards the disease, ensuing of their dominance in the China vaccine market. The authorities have recommended vaccine development, and domestic companies have made substantial development. Factors consisting of developing cognizance of the significance of vaccination and increasing disposable income have also contributed to this dominance.

The DTP vaccine, protecting towards diphtheria, tetanus, and pertussis, has a big percentage within the China vaccine market due to its inclusion in the countrywide immunization application, authorities funding, improved availability and affordability, pertussis outbreaks, and established safety and efficacy, building trust some of the population.

Report Details:

Diseases – China Vaccine Market in has been covered from 6 viewpoints

1.    Meningococcal Meningitis
2.    Pneumococcal
3.    DTP
4.    Ebola
5.    Rabies
6.    Others

PCV 13 has hegemony in the China Vaccine Market.

PCV 13 is dominant in the China vaccine market due to its inclusion in the countrywide immunization program as a Category 1 vaccine and the government's large investment inside the vaccine industry. Pneumococcal sickness is normal among young kids in China, and PCV thirteen has high efficacy in stopping it. Its validated safety and effectiveness have additionally contributed to constructing believe some of the Chinese populace.

Products – China Vaccine Market in has been protected from 7 viewpoints

1.    MCV4
2.    MPSV4
3.    MCV2-Hib
4.    MCV2
5.    MPSV2 and Men A
6.    PCV13
7.    PPV23

Competitive Landscape

The report includes coverage of numerous keyplayers in the China vaccine market, including Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, Shenzhen Kangtai Biological Products Co Ltd.

The increasing significance of vaccination in the Chinese population has caused heightened competition in the China vaccine market. More companies are getting into the market due to the growing demand. The Chinese government encouragement of vaccine improvement has attracted greater investment and elevated opposition among manufacturers. The variety of vaccines focused on distinctive sicknesses and illnesses has created a competitive environment for producers to capture a bigger market share. Pricing, protection, and efficacy are essential factors influencing market opposition among vaccine manufacturers.

Key Players- All the foremost players of the China Vaccine Market have been covered from 3 Viewpoints

1.    Overview
2.    Strategy
3.    Financial Insight

Key Company Covered

1.    Sinopharm Group (China National Biotec Group Company Limited)
2.    Hualan Biological Engineering Inc
3.    Chongqing Zhifei Biological Products Co Ltd
4.    Walvax Biotechnology Co Ltd
5.    Beijing Tiantan Biological Products Corp Ltd
6.    Sinovac Biotech
7.    Shenzhen Kangtai Biological Products Co Ltd

About Us

Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys, and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Contact Us
Renub Research
Phone: +1-478-202-3244 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research